BPG is committed to discovery and dissemination of knowledge
Articles in Press
12/22/2025 7:49:47 AM | Browse: 7 | Download: 0
| Category |
Surgery |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Kyle R Stephens, Megan Wilson, Manting Xu, Jeremy T Gaskins, Gina Genova and Robert C G Martin II |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Robert C G Martin II, MD, PhD, Division of Surgical Oncology, Hiram C Polk Jr, MD, Department of Surgery, University of Louisville, 315 E Broadway, Louisville, KY 40202, United States. robert.martin@louisville.edu |
| Key Words |
Hepatocellular carcinoma; Biomarker; Serum; Recurrence; Mac-2 binding protein glycosylation isomer |
| Core Tip |
Predicting tumor recurrence following curative treatment for hepatocellular carcinoma (HCC) remains a challenging task. Numerous novel biomarkers have been investigated for their ability to predict disease prognosis, as there is a clear need for noninvasive serum assays that can reliably assess the risk for post-treatment recurrence. Mac-2 binding protein glycosylation isomer (M2BPGi) has emerged as a serum biomarker for liver fibrosis, an important component of HCC pathogenesis. Our meta-analysis demonstrates M2BPGi’s utility as a pre-operative predictor of HCC recurrence. |
| Citation |
Stephens KR, Wilson M, Xu M, Gaskins JT, Genova G, Martin II RCG. Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma. World J Gastroenterol 2025; In press |
 |
Received |
|
2025-09-01 09:46 |
 |
Peer-Review Started |
|
2025-09-01 09:48 |
 |
First Decision by Editorial Office Director |
|
2025-10-18 02:31 |
 |
Return for Revision |
|
2025-10-18 02:31 |
 |
Revised |
|
2025-10-31 21:27 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2025-12-22 02:39 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2025-12-22 07:49 |
 |
Articles in Press |
|
2025-12-22 07:49 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345